Neuropsychological evaluation in patients with multiple sclerosis relapse remission in treatment with Rebif

Authors

  • Ivette Cabrera Abreu
  • Amado Díaz de la Fe
  • Margarita Baez Martin
  • Francisca Zamora Pérez
  • María Isabel Martínez Martin
  • María de los Ángeles Robinson Agramonte
  • Belsis Díaz Rondón

Keywords:

multiple sclerosis, cognitive impairment, neurosycholgycal assessment

Abstract

Introduction. Multiple sclerosis is a chronic inflammatory demyelinating disease of the central nervous system. It is considered as the most prevalent and disabling non-traumatic disease affecting the population of young and middle-aged adults. The presence of cognitive affections in these patients is known.

Objectives. To describe the superior psychic functions in patients with Multiple Sclerosis treated and not treated with Rebif and to identify the most affected functions.

Methods. We studied 26 patients treated at the International Center for Neurological Restoration, divided into two groups: 13 patients with Multiple Sclerosis (treated with Rebif) and 13 untreated patients. The clinical variables, such as subtype of MS, duration of disease, medication and neuropsychological profile were analyzed

Results. the study showed that most of the patients treated and not treated with Rebif presented cognitive alterations. The most affected functions were attention, long-term memory and executive functions. Patients treated with Rebif reported fewer symptoms of depression than those not treated. No relationship was found between clinical variables and cognitive impairment. Conclusions. The Superior Psychic Functions are affected in patients with Multiple Sclerosis treated and not treated with Rebif. Depression was lower in patients treated with Rebif.

Downloads

Published

2022-12-31

How to Cite

1.
Cabrera Abreu I, Díaz de la Fe A, Baez Martin M, Zamora Pérez F, Martínez Martin MI, Robinson Agramonte M de los Ángeles, et al. Neuropsychological evaluation in patients with multiple sclerosis relapse remission in treatment with Rebif. Invest Medicoquir [Internet]. 2022 Dec. 31 [cited 2025 Dec. 23];15(1):e799. Available from: https://revcimeq.sld.cu/index.php/imq/article/view/799

Issue

Vol. 15 No. 1 (2023): January-June

Section

Research article

License

The authors retain copyright and all unrestricted publication rights.

Medicoquirúrgicas Research is licensed under the Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0) and follows the SciELO Publishing Schema (SciELO PS) for publishing in XML format.

You are free to:

  • Share — copy and redistribute the material in any medium or format.
  • Adapt — remix, transform, and build upon the material.

The license cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do this in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Non-Commercial — You may not use the material for commercial purposes.
No Additional Restrictions — You may not apply legal terms or technological measures that legally restrict others from making any use permitted by the license.

Notices:

You do not have to comply with the license for elements of the material in the public domain or where their use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all the permissions you need for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.